Myriad Genetics (MYGN) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mail
Get Alerts MYGN Hot Sheet
Price: $5.57 +0.54%
Revenue Growth %: -7.0%
Financial Fact:
Selling, general, and administrative expense: 111.9M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Revenue Growth %: -7.0%
Financial Fact:
Selling, general, and administrative expense: 111.9M
Today's EPS Names:
FNLC, LSBK, OVLY, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q3 EPS of ($0.02), in-line with the analyst estimate of ($0.02). Revenue for the quarter came in at $167.3 million versus the consensus estimate of $165.04 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- Southern Missouri Bancorp (SMBC) Tops Q1 EPS by 7c
- Getty Realty (GTY) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
